Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
6/22/22 | Galderma | Nemolizumab for Pruritus | Subscribers Only | Subscribers Only | Subscribers Only |
6/22/22 | CymaBay Therapeutics (CBAY) | Seladelpar for Primary Biliary Cholangitis (PBC) and Hepatic Fibrosis | Subscribers Only | Subscribers Only | Subscribers Only |
6/21/22 | Ionis Pharmaceuticals (IONS) | Eplontersen for Hereditary Transthyretin (hATTR) Amyloidosis With Polyneuropathy (Familial Amyloid Polyneuropathy) | Subscribers Only | Subscribers Only | Subscribers Only |
6/21/22 | Merck (MRK) | V116 for Pneumococcal (Streptococcus pneumoniae) Vaccines (Antibacterial) | Subscribers Only | Subscribers Only | Subscribers Only |
6/17/22 | ACADIA Pharmaceuticals (ACAD) | Nuplazid for Dementia | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
12/31/02 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation (Emerging Markets) |
06/25/22 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
06/25/22 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
06/25/22 | Subscribers Only | Subscribers Only | Trial Data - Other |
06/25/22 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |